- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Thomas E. Hutson, DO, PharmD | Authors
Cytoreductive Nephrectomies for Renal Cell Carcinoma
May 19, 2022
Drs Thomas Hutson and Scott Tykodi explain when to consider a debulking surgery for patients with renal cell carcinoma.
Sequencing Strategies for Renal Cell Carcinoma Treatment Regimens
May 12, 2022
A look at how to best sequence therapies for renal cell carcinoma from the front-line setting on.
Side Effects of IO/TKI Treatment Regimens for Renal Cell Carcinoma
May 12, 2022
Thought leaders explain how they dose IO/TKI treatment regimens to better manage side effects in patients with renal cell carcinoma.
Advice for Community Oncologists Treating Renal Cell Carcinoma
May 09, 2022
Dr Scott Tykodi provides advice for community oncologists managing patients with renal cell carcinoma.
The Influence of Risk Category Stratification Algorithms on CLEAR Trial Data
March 31, 2022
Thomas Hutson, DO, PharmD, and Scott Tykodi, MD, PhD, discuss their takeaways from the CLEAR trial and how risk category stratification affected the study.
A Role for Single Agent TKI Therapies in Treating Renal Cell Carcinoma
March 31, 2022
Oncologists debate whether TKI monotherapy has a place in renal cell carcinoma treatment after the CLEAR trial.